Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) FCF Margin (2020 - 2024)

Goldenwell Biotech (GWLL) has disclosed FCF Margin for 5 consecutive years, with 16044.94% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, FCF Margin rose 2338186.0% year-over-year to 16044.94%, compared with a TTM value of 18437.97% through Sep 2025, up 3865377.0%, and an annual FY2024 reading of 88544.6%, down 8238159.0% over the prior year.
  • FCF Margin was 16044.94% for Q4 2024 at Goldenwell Biotech, up from 16077.78% in the prior quarter.
  • Across five years, FCF Margin topped out at 22313.63% in Q4 2022 and bottomed at 36688.92% in Q1 2022.
  • Average FCF Margin over 5 years is 5447.29%, with a median of 2542.4% recorded in 2020.
  • Peak annual rise in FCF Margin hit 3444412bps in 2023, while the deepest fall reached -2965055bps in 2023.
  • Year by year, FCF Margin stood at 2840.0% in 2020, then surged by 75bps to 718.85% in 2021, then skyrocketed by 3204bps to 22313.63% in 2022, then tumbled by -133bps to 7336.92% in 2023, then surged by 319bps to 16044.94% in 2024.
  • Business Quant data shows FCF Margin for GWLL at 16044.94% in Q4 2024, 16077.78% in Q2 2024, and 7336.92% in Q4 2023.